Front. Oncol., 29 May 2012 |

The first European interdisciplinary Ewing sarcoma research summit

Heinrich Kovar1,26*, Javier Alonso2, Pierre Aman3, Dave N. T. Aryee1,26, Jozef Ban1, Sue A. Burchill4, Stefan Burdach5, Enrique De Alava6, Olivier Delattre7, Uta Dirksen8, Argyro Fourtouna1, Simone Fulda9, Lee J. Helman10, David Herrero-Martin1, Pancras C. W. Hogendoorn11, Udo Kontny12, Elizabeth R. Lawlor13,14, Stephen L. Lessnick15, Antonio Llombart-Bosch16, Markus Metzler17, Richard Moriggl18, Stephan Niedan1, Jenny Potratz8, Françoise Redini19, Günther H. S. Richter5, Lucia T. Riedmann1, Claudia Rossig8, Beat W. Schäfer20, Raphaela Schwentner1, Katia Scotlandi21, Poul H. Sorensen22, Martin S. Staege23, Franck Tirode7, Jeffrey Toretsky24, Selena Ventura20, Angelika Eggert25 and Ruth Ladenstein1,26
  • 1 Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria
  • 2 Unidad de Tumores Sólidos Infantiles, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain
  • 3 Department of Pathology, Sahlgrenska Cancer Center, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
  • 4 Leeds Institute of Molecular Medicine, Leeds, UK
  • 5 Children’s Cancer Research Center and Roman Herzog Comprehensive Cancer Center, Klinikum rechts der Isar, Technical University, Munich, Germany
  • 6 Department of Pathology, University Hospital of Salamanca, Cancer Research Center-IBMCC, University of Salamanca-CSIC, Salamanca, Spain
  • 7 INSERM, U830 Génétique et Biologie des Cancers, Institut Curie, Paris, France
  • 8 Pediatric Hematology and Oncology, University Children’s Hospital Münster, Münster, Germany
  • 9 Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Frankfurt am Main, Germany
  • 10 Molecular Oncology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
  • 11 Department of Pathology, Leiden University Medical Centre, Leiden, Netherlands
  • 12 Division of Pediatric Hematology and Oncology, University Children’s Hospital, Freiburg, Germany
  • 13 Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA
  • 14 Department of Pathology, University of Michigan, Ann Arbor, MI, USA
  • 15 Division of Pediatric Hematology and Oncology, Department of Oncological Sciences, Center for Children’s Cancer Research at Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA
  • 16 Department of Pathology, University of Valencia, Valencia, Spain
  • 17 University Children’s Hospital, Erlangen, Germany
  • 18 Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria
  • 19 INSERM, UMR 957, LUNAM Université, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives EA3822, Nantes, France
  • 20 Department of Oncology, University Children’s Hospital, Zurich, Switzerland
  • 21 CRS Development of Biomolecular Therapies, Laboratory of Experimental Oncology, Rizzoli Institute, Bologna, Italy
  • 22 Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada
  • 23 Department of Pediatrics, Children’s Cancer Research Centre, Martin-Luther-University Halle-Wittenberg, Halle, Germany
  • 24 Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
  • 25 Department of Pediatric Oncology and Hematology, University Children’s Hospital, Essen, Germany
  • 26 Department of Pediatrics, Medical University, Vienna, Austria

The European Network for Cancer Research in Children and Adolescents (ENCCA) provides an interaction platform for stakeholders in research and care of children with cancer. Among ENCCA objectives is the establishment of biology-based prioritization mechanisms for the selection of innovative targets, drugs, and prognostic markers for validation in clinical trials. Specifically for sarcomas, there is a burning need for novel treatment options, since current chemotherapeutic treatment protocols have met their limits. This is most obvious for metastatic Ewing sarcoma (ES), where long term survival rates are still below 20%. Despite significant progress in our understanding of ES biology, clinical translation of promising laboratory results has not yet taken place due to fragmentation of research and lack of an institutionalized discussion forum. To fill this gap, ENCCA assembled 30 European expert scientists and five North American opinion leaders in December 2011 to exchange thoughts and discuss the state of the art in ES research and latest results from the bench, and to propose biological studies and novel promising therapeutics for the upcoming European EWING2008 and EWING2012 clinical trials.

Keywords: Ewing sarcoma, animal models, sarcomagenesis, genomics, epigenetics, biomarkers, drug screen, prognosis

Citation: Kovar H, Alonso J, Aman P, Aryee DNT, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PCW, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Redini F, Richter GHS, Riedmann LT, Rossig C, Schäfer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A and Ladenstein R (2012) The first European interdisciplinary Ewing sarcoma research summit. Front. Oncol. 2:54. doi: 10.3389/fonc.2012.00054

Received: 15 March 2012; Paper pending published: 17 April 2012;
Accepted: 10 May 2012; Published online: 29 May 2012.

Edited by:

Brigitte Charolotte Widemann, National Cancer Institute, USA

Reviewed by:

David Loeb, Johns Hopkins University, USA
Gareth J. Veal, Newcastle University, UK

Copyright: © 2012 Kovar, Alonso, Aman, Aryee, Ban, Burchill, Burdach, De Alava, Delattre, Dirksen, Fourtouna, Fulda, Helman, Herrero-Martin, Hogendoorn, Kontny, Lawlor, Lessnick, Llombart-Bosch, Metzler, Moriggl, Niedan, Potratz, Redini, Richter, Riedmann, Rossig, Schäfer, Schwentner, Scotlandi, Sorensen, Staege, Tirode, Toretsky, Ventura, Eggert and Ladenstein. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.

*Correspondence: Heinrich Kovar, Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung and Medical University, Zimmermannplatz 10, 1090 Vienna, Austria. e-mail: